EAPB Forum: 2001/3 Editorial
NewDrugs is the professional magazin for decision makers in the laboratories of pharma companies with their own research activities and for executives in biotech research and service laboratories.
As the official organ of the European Association of Pharma Biotechnology (EAPB), New Drugs accompanies the breathtaking progress of technological development in the pharmaceutical laboratory and ensures the speedy transfer of know-how in the areas of genomics, proteomics and laboratory automation. Reports on innovative laboratory technologies, products and processes which are paving the way - and accelerating progress - to a new generation of medicines are rounded off by the latest business bulletins, product reviews and company news.
A high standard of reporting is guaranteed by an scientific advisory board of top-name scientists.
Get to the NewDrugs website
Scientific Editor and Head of the Advisory Board: Conrad J. Coester, Ph.D.
Conrad Coester studied pharmacy between 1992 and 1996 and finished 2000 his Ph.D. in Pharmaceutical Technology at the University of Frankfurt (Germany) under supervision of Prof. Dr. J. Kreuter in the area of colloidal drug delivery systems. After working as a Postdoctoral Fellow at the Faculty for Pharmacy, University of Alberta in Edmonton (Canada) for 18 month he became in September 2002 head of the research group nanoparticulate Drug Delivery Systems on the position of a scientific assistant in Pharmaceutical Technology at the University of Munich (Germany). From January 2003 he was additionally appointed as adjunct Professor at the Faculty for Pharmacy, University of Alberta in order to co-supervise different graduate students in the field of colloidal drug carrier systems. Aside his research work he is teaching different lab and lecture courses in Pharmaceutical Technology and Biopharmaceutics in the undergraduate program. Since 3 years Conrad Coester is reviewer for several international journals and joined the scientific advisory board of NewDrugs in 2002. His scientific output comprises 10 primary scientific papers, 12 poster presentations at international conferences, 14 international oral presentations and 2 patents/patent applications.